Mira Pharmaceuticals (MIRA) Total Liabilities (2022 - 2025)
Mira Pharmaceuticals (MIRA) posted Total Liabilities of $702068.0 for Q4 2025, up 736.53% sequentially from $83926.0 in Q3 2025, and down 2.94% YoY from $723349.0 in Q4 2024.
Mira Pharmaceuticals (MIRA) Total Liabilities (2022 - 2025) Analysis & Trends
Mira Pharmaceuticals has reported Total Liabilities for 4 years, with the latest figure at $702068.0 in Q4 2025.
- Quarterly Total Liabilities fell 2.94% year-over-year to $702068.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $702068.0 (down 2.94% YoY) and the FY2025 annual result came in at $702068.0, down 2.94% from the prior year.
- Total Liabilities advanced to $702068.0 in Q4 2025 per MIRA's latest filing, from $83926.0 in the prior quarter.
- Over five years, Total Liabilities peaked at $2.6 million in Q2 2023 and troughed at $83926.0 in Q3 2025.
- A 4-year average of $800239.5 and a median of $692833.0 in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Liabilities climbed 29.61% in 2024, then sank 87.89% in 2025.
- Over 4 years, Total Liabilities stood at $1.5 million in 2022, then slumped by 61.62% to $558097.0 in 2023, then grew by 29.61% to $723349.0 in 2024, then retreated by 2.94% to $702068.0 in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $702068.0, $83926.0, and $298459.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 116.09 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 80.09 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 65.46 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 115.64 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -59.79 Bn |
| 10 | Mira Pharmaceuticals | 18.47 Mn | 7.44 Mn | - | 702,068.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 702,068.00 |
| Sep 30, 2025 | 83,926.00 |
| Jun 30, 2025 | 298,459.00 |
| Mar 31, 2025 | 106,173.00 |
| Dec 31, 2024 | 723,349.00 |
| Sep 30, 2024 | 692,833.00 |
| Mar 31, 2024 | 652,006.00 |
| Dec 31, 2023 | 558,097.00 |
| Sep 30, 2023 | 902,901.00 |
| Jun 30, 2023 | 2.63 Mn |
| Dec 31, 2022 | 1.45 Mn |